The Drug Stock that's Tripled in Value Today

RDHL is sinking after disappointing drug-trial results

Managing Editor
Oct 3, 2017 at 3:00 PM
facebook X logo linkedin


U.S. stocks are trading higher again this afternoon, with the S&P 500 Index, Dow and Nasdaq Composite all touching fresh intraday record peaks. Airline stock Delta Air Lines, Inc. (NYSE:DAL) is enjoying a strong day, while biopharmaceutical stocks Celsion Corporation (NASDAQ:CLSN) and RedHill Biopharma Ltd (NASDAQ:RDHL) are trending in opposite directions. Here's a quick look at what is moving shares of DAL, CLSN, and RDHL.

Delta Air Lines Stock Taking Off After Encouraging Forecast

Delta Air Lines gave a better-than-expected forecast following the devastation wrought by Hurricane Irma, news that's lifting the wider airline sector. DAL stock, already one of the best stocks to buy in October, is currently up 6.5% to trade at $51.18, bringing its year-over-year lead to greater than 28%. This marks the airline's largest one-day gain in over two years and takes the shares past their 80-day moving average for the first time since Aug. 8. Meanwhile, analysts are overwhelmingly upbeat. Of the 15 brokerages covering DAL stock, 14 rate the shares a "buy" or better.

Positive Ovarian Cancer Drug Results Fuel Red-Hot Celsion Stock

Celsion stock has more than tripled in value today, up 250% to trade at $5.31, coming in as the top gainer on the Nasdaq, after encouraging early stage trial results for its stage III ovarian cancer treatment. The stock's performance today represents a whopping 310% increase from its Aug. 22 low of $1.24. The shares are now trading above their 200-day moving average for the first time since July 2015.

A short-squeeze could fuel an extended rally. Short interest decreased by 2.3% during the last reporting period, and represents 10% of CLSN's total available float. It would take roughly a week for the shorts to fully cover their positions, at CLSN's average daily trading volume. This represents a major source of buying power that could enter the market. 

RedHill Biopharma's IBS Drug Fails To Impress Investors, Stock Sinks

RedHill Biopharma stock is down 14% to trade at $9.37, among the worst on the Nasdaq and currently short-sale restricted. Bekinda, the company's drug for irritable bowel syndrome (IBS) met its main goals in a mid-stage study but failed to impress investors with improvement in abdominal pain and overall response. The shares traded as low as $8.80 today, flirting with their July 11 low of $8.16. Continued technical struggles could have analysts reevaluating their upbeat outlooks. Both analysts covering RDHL shares rate it a "strong buy."

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI